{ "instance": { "hook-20220930x10q.htm": { "axisCustom": 1, "axisStandard": 17, "contextCount": 201, "dts": { "calculationLink": { "local": [ "hook-20220930_cal.xml" ] }, "definitionLink": { "local": [ "hook-20220930_def.xml" ] }, "inline": { "local": [ "hook-20220930x10q.htm" ] }, "labelLink": { "local": [ "hook-20220930_lab.xml" ] }, "presentationLink": { "local": [ "hook-20220930_pre.xml" ] }, "schema": { "local": [ "hook-20220930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 418, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 24, "http://www.hookipapharma.com/20220930": 2, "http://xbrl.sec.gov/dei/2022": 5, "total": 31 }, "keyCustom": 74, "keyStandard": 204, "memberCustom": 18, "memberStandard": 24, "nsprefix": "hook", "nsuri": "http://www.hookipapharma.com/20220930", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "role": "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10301 - Disclosure - Collaboration and Licensing Agreements", "role": "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreements", "shortName": "Collaboration and Licensing Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10401 - Disclosure - Fair Value of Financial Assets", "role": "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssets", "shortName": "Fair Value of Financial Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10501 - Disclosure - Property, plant and equipment, net", "role": "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNet", "shortName": "Property, plant and equipment, net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": null, "first": true, "lang": "en-US", "name": "hook:ReceivableResearchIncentiveTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10601 - Disclosure - Receivable research incentive", "role": "http://www.hookipapharma.com/role/DisclosureReceivableResearchIncentive", "shortName": "Receivable research incentive", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": null, "first": true, "lang": "en-US", "name": "hook:ReceivableResearchIncentiveTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10701 - Disclosure - Accrued expenses and other current liabilities", "role": "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities", "shortName": "Accrued expenses and other current liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": null, "first": true, "lang": "en-US", "name": "hook:DisclosureOfLongTermLoansPayableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10801 - Disclosure - Loans payable", "role": "http://www.hookipapharma.com/role/DisclosureLoansPayable", "shortName": "Loans payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": null, "first": true, "lang": "en-US", "name": "hook:DisclosureOfLongTermLoansPayableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10901 - Disclosure - Common stock, Class A common stock and convertible preferred stock", "role": "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStock", "shortName": "Common stock, Class A common stock and convertible preferred stock", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11001 - Disclosure - Stock-based compensation", "role": "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation", "shortName": "Stock-based compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11101 - Disclosure - Income taxes", "role": "http://www.hookipapharma.com/role/DisclosureIncomeTaxes", "shortName": "Income taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11201 - Disclosure - Commitments and contingencies", "role": "http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingencies", "shortName": "Commitments and contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_WD9uMCTYt0SrLjQFxn4TUQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Rx8Dg8hHV0CKvITi7MfdbA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)", "role": "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_WD9uMCTYt0SrLjQFxn4TUQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Rx8Dg8hHV0CKvITi7MfdbA", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11301 - Disclosure - Net loss per share", "role": "http://www.hookipapharma.com/role/DisclosureNetLossPerShare", "shortName": "Net loss per share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11401 - Disclosure - Subsequent Events", "role": "http://www.hookipapharma.com/role/DisclosureSubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "20202 - Disclosure - Summary of significant accounting policies (Policies)", "role": "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of significant accounting policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": null, "first": true, "lang": "en-US", "name": "hook:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30203 - Disclosure - Summary of significant accounting policies (Tables)", "role": "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of significant accounting policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": null, "first": true, "lang": "en-US", "name": "hook:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30403 - Disclosure - Fair Value of Financial Assets (Tables)", "role": "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsTables", "shortName": "Fair Value of Financial Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30503 - Disclosure - Property, plant and equipment, net (Tables)", "role": "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetTables", "shortName": "Property, plant and equipment, net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": null, "first": true, "lang": "en-US", "name": "hook:ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30703 - Disclosure - Accrued expenses and other current liabilities (Tables)", "role": "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables", "shortName": "Accrued expenses and other current liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": null, "first": true, "lang": "en-US", "name": "hook:ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "hook:DisclosureOfLongTermLoansPayableTextBlock", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": null, "first": true, "lang": "en-US", "name": "hook:DisclosureOfLongTermLoansPayableTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30803 - Disclosure - Loans payable (Tables)", "role": "http://www.hookipapharma.com/role/DisclosureLoansPayableTables", "shortName": "Loans payable (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "hook:DisclosureOfLongTermLoansPayableTextBlock", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": null, "first": true, "lang": "en-US", "name": "hook:DisclosureOfLongTermLoansPayableTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31003 - Disclosure - Stock-based compensation (Tables)", "role": "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationTables", "shortName": "Stock-based compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31303 - Disclosure - Net loss per share (Tables)", "role": "http://www.hookipapharma.com/role/DisclosureNetLossPerShareTables", "shortName": "Net loss per share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_WD9uMCTYt0SrLjQFxn4TUQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_slztR1gY5UyNCxLijJYj0g", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)", "role": "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_WD9uMCTYt0SrLjQFxn4TUQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_slztR1gY5UyNCxLijJYj0g", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_Dntv7LbacESDS1BcijZabg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_Rx8Dg8hHV0CKvITi7MfdbA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40201 - Disclosure - Summary of significant accounting policies - Going concern (Details)", "role": "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesGoingConcernDetails", "shortName": "Summary of significant accounting policies - Going concern (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R31": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "hook:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_h3Pdyecu5U2bx3Fc5tZQ9Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40202 - Disclosure - Summary of significant accounting policies - Property and equipment (Details)", "role": "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails", "shortName": "Summary of significant accounting policies - Property and equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "hook:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_h3Pdyecu5U2bx3Fc5tZQ9Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": "INF", "first": true, "lang": null, "name": "hook:CollaborativeArrangementNumberOfPreclinicalResearchPrograms", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_Program_t24iTFrZxEiIxtk34MxItg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40203 - Disclosure - Summary of significant accounting policies - Others (Details)", "role": "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOthersDetails", "shortName": "Summary of significant accounting policies - Others (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": "INF", "first": true, "lang": null, "name": "hook:CollaborativeArrangementNumberOfPreclinicalResearchPrograms", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_Program_t24iTFrZxEiIxtk34MxItg", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_6_1_2018_To_6_30_2018_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_aCGznGY6HEOtvv7b_hWCYg", "decimals": "INF", "first": true, "lang": null, "name": "hook:NumberOfPreclinicalResearchPrograms", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_0OXW2Kd5w0Os4aekYa9OKA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40301 - Disclosure - Collaboration and Licensing Agreements (Details)", "role": "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails", "shortName": "Collaboration and Licensing Agreements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_6_1_2018_To_6_30_2018_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_aCGznGY6HEOtvv7b_hWCYg", "decimals": "INF", "first": true, "lang": null, "name": "hook:NumberOfPreclinicalResearchPrograms", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_0OXW2Kd5w0Os4aekYa9OKA", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Rx8Dg8hHV0CKvITi7MfdbA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40401 - Disclosure - Fair Value of Financial Assets (Details)", "role": "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails", "shortName": "Fair Value of Financial Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Rx8Dg8hHV0CKvITi7MfdbA", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_WD9uMCTYt0SrLjQFxn4TUQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Rx8Dg8hHV0CKvITi7MfdbA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40501 - Disclosure - Property, plant and equipment, net (Details)", "role": "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails", "shortName": "Property, plant and equipment, net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_WD9uMCTYt0SrLjQFxn4TUQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Rx8Dg8hHV0CKvITi7MfdbA", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_WD9uMCTYt0SrLjQFxn4TUQ", "decimals": "-3", "first": true, "lang": null, "name": "hook:ReceivablesTaxResearchPremiumCurrent", "reportCount": 1, "unitRef": "Unit_Standard_USD_Rx8Dg8hHV0CKvITi7MfdbA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40601 - Disclosure - Receivable research incentive (Details)", "role": "http://www.hookipapharma.com/role/DisclosureReceivableResearchIncentiveDetails", "shortName": "Receivable research incentive (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_Dntv7LbacESDS1BcijZabg", "decimals": "-5", "lang": null, "name": "hook:GrantIncomeIncentiveProgram", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Rx8Dg8hHV0CKvITi7MfdbA", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "hook:ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_WD9uMCTYt0SrLjQFxn4TUQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccruedEmployeeBenefitsCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Rx8Dg8hHV0CKvITi7MfdbA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40701 - Disclosure - Accrued expenses and other current liabilities (Details)", "role": "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails", "shortName": "Accrued expenses and other current liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "hook:ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_WD9uMCTYt0SrLjQFxn4TUQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccruedEmployeeBenefitsCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Rx8Dg8hHV0CKvITi7MfdbA", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "hook:DisclosureOfLongTermLoansPayableTableTextBlock", "hook:DisclosureOfLongTermLoansPayableTextBlock", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_WD9uMCTYt0SrLjQFxn4TUQ", "decimals": "-3", "first": true, "lang": null, "name": "hook:LongTermLoansPayableGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Rx8Dg8hHV0CKvITi7MfdbA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40801 - Disclosure - Loans payable (Details)", "role": "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails", "shortName": "Loans payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "hook:DisclosureOfLongTermLoansPayableTableTextBlock", "hook:DisclosureOfLongTermLoansPayableTextBlock", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_WD9uMCTYt0SrLjQFxn4TUQ", "decimals": "-3", "first": true, "lang": null, "name": "hook:LongTermLoansPayableGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Rx8Dg8hHV0CKvITi7MfdbA", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_WD9uMCTYt0SrLjQFxn4TUQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Rx8Dg8hHV0CKvITi7MfdbA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40802 - Disclosure - Loans payable - Schedule of aggregate minimum future principal payments (Details)", "role": "http://www.hookipapharma.com/role/DisclosureLoansPayableScheduleOfAggregateMinimumFuturePrincipalPaymentsDetails", "shortName": "Loans payable - Schedule of aggregate minimum future principal payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_WD9uMCTYt0SrLjQFxn4TUQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Rx8Dg8hHV0CKvITi7MfdbA", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_Dntv7LbacESDS1BcijZabg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Rx8Dg8hHV0CKvITi7MfdbA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED)", "role": "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_Dntv7LbacESDS1BcijZabg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Rx8Dg8hHV0CKvITi7MfdbA", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_WD9uMCTYt0SrLjQFxn4TUQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "Unit_Standard_shares_4AEB4RE7d0OQvhn5udDBgA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40901 - Disclosure - Common stock, Class A common stock and convertible preferred stock (Details)", "role": "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails", "shortName": "Common stock, Class A common stock and convertible preferred stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_3_4_2022_To_3_4_2022_CLw8kg5A10-mnqKQgLBbmQ", "decimals": "-5", "lang": null, "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Rx8Dg8hHV0CKvITi7MfdbA", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_WD9uMCTYt0SrLjQFxn4TUQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Unit_Standard_shares_4AEB4RE7d0OQvhn5udDBgA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41001 - Disclosure - Stock-based compensation - 2018 Stock Option and Grant Plan (Details)", "role": "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails", "shortName": "Stock-based compensation - 2018 Stock Option and Grant Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_us-gaap_PlanNameAxis_hook_StockOptionAndGrant2018PlanMember_FDfU2zrIsUWH-QCyhr2eUw", "decimals": null, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_4_1_2019_To_4_1_2019_dTBJHbszfUm9UNpLfSi21g", "decimals": "INF", "first": true, "lang": null, "name": "hook:ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_4AEB4RE7d0OQvhn5udDBgA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41002 - Disclosure - Stock-based compensation - 2019 Stock Option and Incentive Plan (Details)", "role": "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails", "shortName": "Stock-based compensation - 2019 Stock Option and Incentive Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_4_1_2019_To_4_1_2019_dTBJHbszfUm9UNpLfSi21g", "decimals": "INF", "first": true, "lang": null, "name": "hook:ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_4AEB4RE7d0OQvhn5udDBgA", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_7_1_2021_To_9_30_2021_s7hUfcujPkmS4ZcHncxJRw", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_v69NDmCap0C7a_7m_cXIFg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41003 - Disclosure - Stock-based compensation - Stock option valuation (Details)", "role": "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionValuationDetails", "shortName": "Stock-based compensation - Stock option valuation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_7_1_2021_To_9_30_2021_s7hUfcujPkmS4ZcHncxJRw", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_v69NDmCap0C7a_7m_cXIFg", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "As_Of_12_31_2021_V5aLA3yCeUqpFVfky43Mew", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Unit_Standard_shares_4AEB4RE7d0OQvhn5udDBgA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41004 - Disclosure - Stock-based compensation - Stock option activity (Details)", "role": "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "shortName": "Stock-based compensation - Stock option activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_4AEB4RE7d0OQvhn5udDBgA", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "As_Of_3_31_2022_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_qJww2owFAkO9hfEzoif2OA", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_slztR1gY5UyNCxLijJYj0g", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41005 - Disclosure - Stock-based compensation - Common Stock Awards (Details)", "role": "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationCommonStockAwardsDetails", "shortName": "Stock-based compensation - Common Stock Awards (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "As_Of_3_31_2022_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_qJww2owFAkO9hfEzoif2OA", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_slztR1gY5UyNCxLijJYj0g", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_Dntv7LbacESDS1BcijZabg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unitRef": "Unit_Standard_USD_Rx8Dg8hHV0CKvITi7MfdbA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41006 - Disclosure - Stock-based compensation - Stock-based compensation (Details)", "role": "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails", "shortName": "Stock-based compensation - Stock-based compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_8dlbYxan7EyEqZmJHTve_w", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Rx8Dg8hHV0CKvITi7MfdbA", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "hook:IncomeTaxBenefitsNetOperatingLossesIncurred", "hook:IncomeTaxBenefitsNetOperatingLossesIncurred", "hook:IncomeTaxBenefitsNetOperatingLossesIncurred", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_Dntv7LbacESDS1BcijZabg", "decimals": "-3", "first": true, "lang": null, "name": "hook:IncomeTaxBenefitsNetOperatingLossesIncurred", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Rx8Dg8hHV0CKvITi7MfdbA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41101 - Disclosure - Income taxes (Details)", "role": "http://www.hookipapharma.com/role/DisclosureIncomeTaxesDetails", "shortName": "Income taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "hook:IncomeTaxBenefitsNetOperatingLossesIncurred", "hook:IncomeTaxBenefitsNetOperatingLossesIncurred", "hook:IncomeTaxBenefitsNetOperatingLossesIncurred", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_Dntv7LbacESDS1BcijZabg", "decimals": "-3", "first": true, "lang": null, "name": "hook:IncomeTaxBenefitsNetOperatingLossesIncurred", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Rx8Dg8hHV0CKvITi7MfdbA", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_WD9uMCTYt0SrLjQFxn4TUQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RestrictedCashNoncurrent", "reportCount": 1, "unitRef": "Unit_Standard_USD_Rx8Dg8hHV0CKvITi7MfdbA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41201 - Disclosure - Commitments and contingencies - Operating and Finance Leases (Details)", "role": "http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingenciesOperatingAndFinanceLeasesDetails", "shortName": "Commitments and contingencies - Operating and Finance Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_WD9uMCTYt0SrLjQFxn4TUQ", "decimals": "-5", "lang": null, "name": "us-gaap:OperatingLeaseLiability", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Rx8Dg8hHV0CKvITi7MfdbA", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_WD9uMCTYt0SrLjQFxn4TUQ", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ContractualObligation", "reportCount": 1, "unitRef": "Unit_Standard_USD_Rx8Dg8hHV0CKvITi7MfdbA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41202 - Disclosure - Commitments and contingencies - Others (Details)", "role": "http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingenciesOthersDetails", "shortName": "Commitments and contingencies - Others (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_Dntv7LbacESDS1BcijZabg", "decimals": "-5", "lang": null, "name": "hook:LicensingFeesIntellectualPropertyLicenses", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Rx8Dg8hHV0CKvITi7MfdbA", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_hook_ConvertiblePreferredStocksMember_EOMnp8l9GU2x1HBXTk5aoA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "Unit_Standard_USD_Rx8Dg8hHV0CKvITi7MfdbA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (UNAUDITED)", "role": "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_hook_CommonStockOtherThanClassMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BeIatW7VJ0iIvN9jcsALzw", "decimals": "-3", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Rx8Dg8hHV0CKvITi7MfdbA", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_Dntv7LbacESDS1BcijZabg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_Rx8Dg8hHV0CKvITi7MfdbA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41301 - Disclosure - Net loss per share (Details)", "role": "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails", "shortName": "Net loss per share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_Dntv7LbacESDS1BcijZabg", "decimals": "0", "lang": null, "name": "hook:WeightedAverageNumberOfSharesOutstandingBasicAndDilutedBeforeConversion", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_4AEB4RE7d0OQvhn5udDBgA", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_4AEB4RE7d0OQvhn5udDBgA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41302 - Disclosure - Net loss per share - Antidilutive securities (Details)", "role": "http://www.hookipapharma.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails", "shortName": "Net loss per share - Antidilutive securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_4AEB4RE7d0OQvhn5udDBgA", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "reportCount": 1, "unitRef": "Unit_Divide_USD_shares_slztR1gY5UyNCxLijJYj0g", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41401 - Disclosure - Subsequent Events (Details)", "role": "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_10_1_2022_To_10_31_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_1HA3SyaOkEy048bL6d2EqA", "decimals": "2", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_slztR1gY5UyNCxLijJYj0g", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "As_Of_3_31_2022_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_Hvj0ENzYY0CY2g78o-AZdA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_slztR1gY5UyNCxLijJYj0g", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (UNAUDITED) (Parenthetical)", "role": "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnauditedParenthetical", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (UNAUDITED) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "As_Of_3_31_2022_us-gaap_StatementClassOfStockAxis_hook_Seriesa1ConvertiblePreferredStockMember_Hvj0ENzYY0CY2g78o-AZdA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_slztR1gY5UyNCxLijJYj0g", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Rx8Dg8hHV0CKvITi7MfdbA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)", "role": "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Rx8Dg8hHV0CKvITi7MfdbA", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10101 - Disclosure - Nature of the business and organization", "role": "http://www.hookipapharma.com/role/DisclosureNatureOfBusinessAndOrganization", "shortName": "Nature of the business and organization", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10201 - Disclosure - Summary of significant accounting policies", "role": "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of significant accounting policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "hook-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_UYoiqnWCs0uPc4tIVzV68Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 42, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document And Entity Information [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r414" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r415" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r412" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r412" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r419" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r412" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r418" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r412" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r412" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r412" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r412" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r411" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r413" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "hook_AccruedExpensesAndOtherCurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of Amount of expenses incurred but not yet paid nor invoiced current, and liabilities classified as other current.", "label": "Accrued Expenses and Other Current Liabilities.", "terseLabel": "Accrued expenses and other current liabilities", "totalLabel": "Total" } } }, "localname": "AccruedExpensesAndOtherCurrentLiabilities", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "hook_AccruedExpensesAndOtherLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Accrued expenses and other current liabilities" } } }, "localname": "AccruedExpensesAndOtherLiabilitiesCurrentAbstract", "nsuri": "http://www.hookipapharma.com/20220930", "xbrltype": "stringItemType" }, "hook_AccruedExpensesForPropertyAndEquipmentAcquisitions": { "auth_ref": [], "calculation": { "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 8.0, "parentTag": "hook_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying amount as of balance sheet date of accrued expenses for property and equipment acquisitions.", "label": "Accrued Expenses for Property and Equipment Acquisitions", "terseLabel": "Accrued for property and equipment acquisitions" } } }, "localname": "AccruedExpensesForPropertyAndEquipmentAcquisitions", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "hook_AccruedExternalGeneralAndAdministrationExpenses": { "auth_ref": [], "calculation": { "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 7.0, "parentTag": "hook_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying amount as of balance sheet date of accrued external general and administration expenses.", "label": "Accrued External General and Administration Expenses", "terseLabel": "Accrued external general and administration expenses" } } }, "localname": "AccruedExternalGeneralAndAdministrationExpenses", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "hook_AccruedExternalResearchAndDevelopmentExpenses": { "auth_ref": [], "calculation": { "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 6.0, "parentTag": "hook_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying amount as of balance sheet date of accrued external research and development expenses.", "label": "Accrued External Research and Development Expenses", "terseLabel": "Accrued external research and development expenses" } } }, "localname": "AccruedExternalResearchAndDevelopmentExpenses", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "hook_AccruedSocialSecurityContributionsCurrent": { "auth_ref": [], "calculation": { "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 3.0, "parentTag": "hook_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the social security contributions.", "label": "Accrued Social Security Contributions, Current", "terseLabel": "Social security contributions" } } }, "localname": "AccruedSocialSecurityContributionsCurrent", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "hook_AccruedSubLicenseFees": { "auth_ref": [], "calculation": { "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 9.0, "parentTag": "hook_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accrued sub license fees at the balance sheet date.", "label": "Accrued Sub License Fees", "terseLabel": "Sublicense fees" } } }, "localname": "AccruedSubLicenseFees", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "hook_AccruedUnearnedGrantIncomeCurrent": { "auth_ref": [], "calculation": { "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 4.0, "parentTag": "hook_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of accrued unearned grant income (current).", "label": "Accrued Unearned Grant Income , Current", "terseLabel": "Unearned grant income (current)" } } }, "localname": "AccruedUnearnedGrantIncomeCurrent", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "hook_AdjustmentsToAdditionalPaidInCapitalAtMarketIssuanceCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase decrease to additional paid in capital due to at the market issuance cost.", "label": "Adjustments to Additional Paid in Capital, At the Market Issuance Cost", "negatedLabel": "ATM costs" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalAtMarketIssuanceCost", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "hook_CollaborationAgreementMilestonePaymentsRevenueRecognized": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of milestone payments revenue recognized under the collaboration agreement.", "label": "Collaboration Agreement, Milestone Payments, Revenue Recognized", "terseLabel": "Revenue recognized from milestone payments" } } }, "localname": "CollaborationAgreementMilestonePaymentsRevenueRecognized", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "hook_CollaborativeAgreementProgramInitiationFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses relating to program initiation fees under collaborative agreement.", "label": "Collaborative Agreement, Program Initiation Fees", "terseLabel": "Program initiation fee" } } }, "localname": "CollaborativeAgreementProgramInitiationFees", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "hook_CollaborativeAndLicensingArrangementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Collaboration and Licensing Agreements" } } }, "localname": "CollaborativeAndLicensingArrangementAbstract", "nsuri": "http://www.hookipapharma.com/20220930", "xbrltype": "stringItemType" }, "hook_CollaborativeArrangementContractAssetRelatingToSublicensePayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of contract assets relating to sublicense payment.", "label": "Collaborative Arrangement, Contract Asset Relating to Sublicense Payment", "terseLabel": "Contract asset relating to the sublicense payment" } } }, "localname": "CollaborativeArrangementContractAssetRelatingToSublicensePayment", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "hook_CollaborativeArrangementNumberOfPreclinicalResearchPrograms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of preclinical research programs in collaborative arrangement.", "label": "Collaborative Arrangement, Number of Preclinical Research Programs", "terseLabel": "Number of preclinical research programs" } } }, "localname": "CollaborativeArrangementNumberOfPreclinicalResearchPrograms", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOthersDetails" ], "xbrltype": "integerItemType" }, "hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of revenue from cost reimbursements for research and development services.", "label": "Collaborative Arrangement, Revenue from Cost Reimbursements for Research and Development Services", "terseLabel": "Revenue recognized from cost reimbursements for research and development services" } } }, "localname": "CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServices", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "hook_CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServicesRecordedAsDeferredRevenue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cost reimbursements for research and development services, of which initially recorded as deferred revenue.", "label": "Collaborative Arrangement Revenue From Cost Reimbursements For Research And Development Services Recorded As Deferred Revenue", "terseLabel": "Revenue recognized from cost reimbursements for research and development services initially recorded as deferred revenue" } } }, "localname": "CollaborativeArrangementRevenueFromCostReimbursementsForResearchAndDevelopmentServicesRecordedAsDeferredRevenue", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "hook_CollaborativeArrangementTermOfRoyaltyPayment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The term for royalty payment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Collaborative Arrangement, Term of Royalty Payment", "terseLabel": "Payment term (in days)" } } }, "localname": "CollaborativeArrangementTermOfRoyaltyPayment", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails" ], "xbrltype": "durationItemType" }, "hook_CommercialMilestonesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to commercial milestones.", "label": "Commercial Milestones" } } }, "localname": "CommercialMilestonesMember", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails" ], "xbrltype": "domainItemType" }, "hook_CommonStockOtherThanClassMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock other than Class A common stock.", "label": "Common stock" } } }, "localname": "CommonStockOtherThanClassMember", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails", "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnauditedParenthetical" ], "xbrltype": "domainItemType" }, "hook_ComputerEquipmentAndSoftwareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems and Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.", "label": "Computer equipment and software" } } }, "localname": "ComputerEquipmentAndSoftwareMember", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails", "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "hook_ConversionOfStockCommonStockIssuedForEachShareConverted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of new common stock issued in the conversion of each stock.", "label": "Conversion of Stock, Common Stock Issued for Each Share Converted", "terseLabel": "Number of common stock issued upon conversion of each share" } } }, "localname": "ConversionOfStockCommonStockIssuedForEachShareConverted", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails" ], "xbrltype": "sharesItemType" }, "hook_ConvertiblePreferredStockSeriesaOneSharesIssuableUponConversion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of common stock issuable upon conversion of Series A-1 convertible preferred stock.", "label": "Convertible Preferred Stock, SeriesA One Shares Issuable upon Conversion", "terseLabel": "Number of common stock issuable upon conversion of Series A-1 convertible preferred stock" } } }, "localname": "ConvertiblePreferredStockSeriesaOneSharesIssuableUponConversion", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "hook_ConvertiblePreferredStocksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to convertible preferred stocks.", "label": "Convertible Preferred Stock" } } }, "localname": "ConvertiblePreferredStocksMember", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "hook_DeferredOfferingCostsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for deferred offering costs.", "label": "Deferred Offering Costs, Policy [Policy Text Block]", "terseLabel": "Deferred offering costs" } } }, "localname": "DeferredOfferingCostsPolicyPolicyTextBlock", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "hook_DeferredRevenuePercentageOfRevenueRecognizedInYearOne": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of revenue recognized in year one that was previously reported as deferred or unearned revenue.", "label": "Deferred Revenue, Percentage of Revenue Recognized in Year One", "terseLabel": "Percentage of upfront payment included in deferred revenue expected to be recognized in 2023" } } }, "localname": "DeferredRevenuePercentageOfRevenueRecognizedInYearOne", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails" ], "xbrltype": "percentItemType" }, "hook_DeferredRevenuePercentageOfRevenueRecognizedInYearThree": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of revenue recognized in year three that was previously reported as deferred or unearned revenue.", "label": "Deferred Revenue, Percentage of Revenue Recognized in Year Three", "terseLabel": "Percentage of upfront payment included in deferred revenue expected to be recognized in 2025" } } }, "localname": "DeferredRevenuePercentageOfRevenueRecognizedInYearThree", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails" ], "xbrltype": "percentItemType" }, "hook_DeferredRevenuePercentageOfRevenueRecognizedInYearTwo": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of revenue recognized in year two that was previously reported as deferred or unearned revenue.", "label": "Deferred Revenue, Percentage of Revenue Recognized in Year Two", "terseLabel": "Percentage of upfront payment included in deferred revenue expected to be recognized in 2024" } } }, "localname": "DeferredRevenuePercentageOfRevenueRecognizedInYearTwo", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails" ], "xbrltype": "percentItemType" }, "hook_DeferredRevenuePercentageOfRevenueRecognizedRemainderOfFiscalYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of revenue recognized that was previously reported as deferred or unearned revenue.", "label": "Deferred Revenue, Percentage of Revenue Recognized, Remainder of Fiscal year", "terseLabel": "Percentage of upfront payment included in deferred revenue expected to be recognized in 2022" } } }, "localname": "DeferredRevenuePercentageOfRevenueRecognizedRemainderOfFiscalYear", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails" ], "xbrltype": "percentItemType" }, "hook_DeferredRevenuesCostReimbursementsForResearchAndDevelopmentServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cost reimbursements for research and development services included as a liability in deferred revenues.", "label": "Deferred Revenues, Cost Reimbursements for Research and Development Services", "terseLabel": "Cost reimbursements for research and development services included in deferred revenues" } } }, "localname": "DeferredRevenuesCostReimbursementsForResearchAndDevelopmentServices", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "hook_DeferredRevenuesUpfrontAndMilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of upfront and milestone payments included as a liability in deferred revenues.", "label": "Deferred Revenues, Upfront and Milestone Payments", "terseLabel": "Upfront and milestone payments included in deferred revenues" } } }, "localname": "DeferredRevenuesUpfrontAndMilestonePayments", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "hook_DevelopmentMilestonesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to development milestones.", "label": "Development Milestones" } } }, "localname": "DevelopmentMilestonesMember", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails" ], "xbrltype": "domainItemType" }, "hook_DisclosureOfLongTermLoansPayableTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of loans payable.", "label": "Disclosure of Long Term Loans Payable [Table Text block]", "terseLabel": "Schedule of loans payable" } } }, "localname": "DisclosureOfLongTermLoansPayableTableTextBlock", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureLoansPayableTables" ], "xbrltype": "textBlockItemType" }, "hook_DisclosureOfLongTermLoansPayableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of loans payable.", "label": "Disclosure of Long Term Loans Payable [Text block]", "terseLabel": "Loans payable" } } }, "localname": "DisclosureOfLongTermLoansPayableTextBlock", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureLoansPayable" ], "xbrltype": "textBlockItemType" }, "hook_FairValueAssetsLevel1ToLevel2TransfersAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.", "label": "Fair Value, Assets, Level 1 to Level 2 Transfers, Amount1", "terseLabel": "Transfers from Level 1 to Level 2" } } }, "localname": "FairValueAssetsLevel1ToLevel2TransfersAmount1", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "hook_FairValueAssetsLevel2ToLevel1TransfersAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.", "label": "Fair Value, Assets, Level 2 to Level 1 Transfers, Amount1", "terseLabel": "Transfers from Level 2 to Level 1" } } }, "localname": "FairValueAssetsLevel2ToLevel1TransfersAmount1", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "hook_GileadSciencesIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining Gilead Sciences, Inc.", "label": "Gilead" } } }, "localname": "GileadSciencesIncMember", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails" ], "xbrltype": "domainItemType" }, "hook_GoingConcernPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for going concern.", "label": "Going Concern, Policy [Policy Text Block]", "terseLabel": "Going concern" } } }, "localname": "GoingConcernPolicyPolicyTextBlock", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "hook_GrantIncome": { "auth_ref": [], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of grant income.", "label": "Grant Income", "terseLabel": "Grant income" } } }, "localname": "GrantIncome", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "hook_GrantIncomeIncentiveProgram": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Grant income recognized related to the incentive program during the reporting period.", "label": "Grant Income, Incentive Program", "terseLabel": "Income related to the incentive program recorded as grant income" } } }, "localname": "GrantIncomeIncentiveProgram", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureReceivableResearchIncentiveDetails" ], "xbrltype": "monetaryItemType" }, "hook_HbvProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "HBV program.", "label": "HBV program" } } }, "localname": "HbvProgramMember", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails" ], "xbrltype": "domainItemType" }, "hook_HivProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "HIV program.", "label": "HIV program" } } }, "localname": "HivProgramMember", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails" ], "xbrltype": "domainItemType" }, "hook_IncomeTaxBenefitsNetOperatingLossesIncurred": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income tax benefits recorded for the net operating losses incurred.", "label": "Income Tax benefits, Net Operating Losses Incurred", "terseLabel": "Income tax benefits for the net operating losses incurred" } } }, "localname": "IncomeTaxBenefitsNetOperatingLossesIncurred", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "hook_IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities": { "auth_ref": [], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid and other liabilities.", "label": "Increase (Decrease) in Accrued Liabilities and Other Liabilities", "terseLabel": "Accrued expenses and other liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "hook_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets": { "auth_ref": [], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods and other current assets.", "label": "Increase (Decrease) in Prepaid Expenses and Other Current Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "hook_IncreaseDecreaseInReceivableResearchIncentives": { "auth_ref": [], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount of receivable research incentives.", "label": "Increase (Decrease) in Receivable Research Incentives", "negatedLabel": "Receivable research incentives" } } }, "localname": "IncreaseDecreaseInReceivableResearchIncentives", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "hook_LeaseAssetsDerecognizedUponLeaseCancellation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of right of use assets derecognized upon lease cancellation.", "label": "Lease Assets Derecognized Upon Lease Cancellation", "terseLabel": "Lease assets derecognized upon lease cancellation" } } }, "localname": "LeaseAssetsDerecognizedUponLeaseCancellation", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "hook_LicensingFeesIntellectualPropertyLicenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of licensing fees from intellectual property licenses.", "label": "Licensing fees, Intellectual Property Licenses", "terseLabel": "Licensing fees from intellectual property licenses" } } }, "localname": "LicensingFeesIntellectualPropertyLicenses", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingenciesOthersDetails" ], "xbrltype": "monetaryItemType" }, "hook_LongTermLoansPayableGross": { "auth_ref": [], "calculation": { "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermLoansPayable", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of loans payable, gross.", "label": "Long Term Loans Payable, Gross", "terseLabel": "Loans from FFG" } } }, "localname": "LongTermLoansPayableGross", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails" ], "xbrltype": "monetaryItemType" }, "hook_MilestoneAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by characteristics of milestone payments recognized under the milestone method by arrangement.", "label": "Milestone [Axis]" } } }, "localname": "MilestoneAxis", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails" ], "xbrltype": "stringItemType" }, "hook_MilestoneDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Components of milestones that an entity engage.", "label": "Milestone [Domain]" } } }, "localname": "MilestoneDomain", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails" ], "xbrltype": "domainItemType" }, "hook_NonExecutiveDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to non executive directors.", "label": "Non Executive Directors" } } }, "localname": "NonExecutiveDirectorsMember", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails", "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails" ], "xbrltype": "domainItemType" }, "hook_NumberOfCombinedPerformanceObligationForEachResearchProgram": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of combined performance obligation for each research program.", "label": "Number of Combined Performance Obligation for Each Research Program", "terseLabel": "Number of combined performance obligation for each research program" } } }, "localname": "NumberOfCombinedPerformanceObligationForEachResearchProgram", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOthersDetails" ], "xbrltype": "integerItemType" }, "hook_NumberOfPreclinicalResearchPrograms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of preclinical research programs.", "label": "Number of Preclinical Research Programs", "terseLabel": "Number of preclinical research programs" } } }, "localname": "NumberOfPreclinicalResearchPrograms", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails" ], "xbrltype": "integerItemType" }, "hook_NumberOfResearchProgramPerformanceObligations": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of research program performance obligations.", "label": "Number of Research Program Performance Obligations", "terseLabel": "Number of research program performance obligations" } } }, "localname": "NumberOfResearchProgramPerformanceObligations", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOthersDetails" ], "xbrltype": "integerItemType" }, "hook_NumberOfVotes": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of votes for each share held .", "label": "Number of Votes", "terseLabel": "Number of votes" } } }, "localname": "NumberOfVotes", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails" ], "xbrltype": "integerItemType" }, "hook_OptionExercisePayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Option exercise payment.", "label": "Option Exercise Payment", "terseLabel": "Option exercise payment" } } }, "localname": "OptionExercisePayment", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "hook_OtherAccruedExpensesAndLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 5.0, "parentTag": "hook_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of other accruals and liabilities.", "label": "Other Accrued Expenses and Liabilities, Current", "terseLabel": "Other accruals and liabilities" } } }, "localname": "OtherAccruedExpensesAndLiabilitiesCurrent", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "hook_PreferredStockSharesDesignated": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Total number of shares designated as preferred shares", "label": "Preferred stock shares Designated", "terseLabel": "Preferred stock shares Designated" } } }, "localname": "PreferredStockSharesDesignated", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "hook_PremiumPercentageOnVolumeWeightedAveragePurchasePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents premium percentage on volume weighted average purchase price of shares.", "label": "Premium Percentage on Volume Weighted Average Purchase Price", "terseLabel": "Percentage of premium" } } }, "localname": "PremiumPercentageOnVolumeWeightedAveragePurchasePrice", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails" ], "xbrltype": "percentItemType" }, "hook_PrepaidExpensesAndOtherCurrentAssets": { "auth_ref": [], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs and other other current assets.", "label": "Prepaid Expenses and Other Current Assets", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssets", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "hook_ProceedsFromMilestonePayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount received from milestone payment.", "label": "Proceeds From Milestone Payment", "terseLabel": "Milestone payment received" } } }, "localname": "ProceedsFromMilestonePayment", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "hook_ProceedsFromNonRefundableUpFrontPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash inflow from non-refundable upfront payment.", "label": "Proceeds from Non-Refundable, Up-front Payment", "terseLabel": "Upfront payment received" } } }, "localname": "ProceedsFromNonRefundableUpFrontPayment", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails", "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "hook_PropertyAndEquipmentAdditionsInAccountsPayableAndAccruedExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of property and equipment additions in accounts payable and accrued expenses.", "label": "Property and Equipment Additions in Accounts Payable and Accrued Expenses", "negatedLabel": "Property and equipment additions in accounts payable and accrued expenses" } } }, "localname": "PropertyAndEquipmentAdditionsInAccountsPayableAndAccruedExpenses", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "hook_PublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of stock by a private company to the public.", "label": "Public offering", "terseLabel": "Public offering" } } }, "localname": "PublicOfferingMember", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnauditedParenthetical" ], "xbrltype": "domainItemType" }, "hook_ReceivableResearchIncentiveAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "n/a.", "label": "Receivable research incentive" } } }, "localname": "ReceivableResearchIncentiveAbstract", "nsuri": "http://www.hookipapharma.com/20220930", "xbrltype": "stringItemType" }, "hook_ReceivableResearchIncentiveTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for receivable research incentive.", "label": "Receivable Research Incentive [Text Block]", "terseLabel": "Receivable research incentive" } } }, "localname": "ReceivableResearchIncentiveTextBlock", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureReceivableResearchIncentive" ], "xbrltype": "textBlockItemType" }, "hook_ReceivablesTaxResearchPremiumCurrent": { "auth_ref": [], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The sum of amounts currently receivable from tax research premium. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.", "label": "Receivables Tax Research Premium, Current", "terseLabel": "Receivable research incentives", "verboseLabel": "Receivable research incentive" } } }, "localname": "ReceivablesTaxResearchPremiumCurrent", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureReceivableResearchIncentiveDetails", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "hook_RegisterForResaleOfCommonStockAdditionalIssuances": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period to register for resale the shares of common stock from the additional issuance, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Register for Resale of Common Stock, Additional Issuances", "terseLabel": "Register for resale of common stock" } } }, "localname": "RegisterForResaleOfCommonStockAdditionalIssuances", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails" ], "xbrltype": "durationItemType" }, "hook_RemainingOfCommonStockReservedForFutureIssuance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents amount remaining common stock reserved for future issuance.", "label": "Remaining of Common Stock Reserved for Future Issuance", "terseLabel": "Outstanding amount" } } }, "localname": "RemainingOfCommonStockReservedForFutureIssuance", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails" ], "xbrltype": "monetaryItemType" }, "hook_RocheCollaborationAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information related to Research Collaboration and License Agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc.", "label": "Roche collaboration agreement" } } }, "localname": "RocheCollaborationAgreementMember", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "hook_ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of accrued expenses and other current liabilities.", "label": "Schedule of Accrued Expenses and Other Liabilities, Current [Table Text Block]", "terseLabel": "Schedule of accrued expenses and other current liabilities" } } }, "localname": "ScheduleOfAccruedExpensesAndOtherLiabilitiesCurrentTableTextBlock", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "hook_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Schedule of Property, Plant and Equipment, Useful Life [Table Text Block]", "terseLabel": "Schedule of estimated useful life of each asset" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "hook_Series1ConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "N/A", "label": "Series A -1 Convertible Preferred Stock" } } }, "localname": "Series1ConvertiblePreferredStockMember", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "domainItemType" }, "hook_Seriesa1ConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Series A-1 convertible preferred stock.", "label": "Series A-1 convertible preferred stock" } } }, "localname": "Seriesa1ConvertiblePreferredStockMember", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnauditedParenthetical" ], "xbrltype": "domainItemType" }, "hook_SeriesaAndSeriesaOnePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Series A and Series A-1 preferred stock .", "label": "Series A and Series A-1 convertible preferred stock" } } }, "localname": "SeriesaAndSeriesaOnePreferredStockMember", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails" ], "xbrltype": "domainItemType" }, "hook_SeriesaConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Series A Convertible preferred stock.", "label": "Series A Convertible Preferred Stock" } } }, "localname": "SeriesaConvertiblePreferredStockMember", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "domainItemType" }, "hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based awards granted during the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted In Period Total Fair Value", "terseLabel": "Aggregate fair value of share-based awards granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodTotalFairValue", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationCommonStockAwardsDetails" ], "xbrltype": "monetaryItemType" }, "hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The fair value per common stock used for calculating the intrinsic values.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Fair Value used for Calculating Intrinsic Values", "terseLabel": "Fair value per common stock used for calculating intrinsic values" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueUsedForCalculatingIntrinsicValues", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedAggregateIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of non- vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Non-Vested, Aggregate Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, option unvested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedAggregateIntrinsicValue", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for non- vested options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D'.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Non-Vested, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term, option unvested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedWeightedAverageRemainingContractualTerm", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of quarterly installments of vesting of share-based compensation awards.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Vesting, Number of Quarterly Installment", "terseLabel": "Number of quarterly installments for vesting" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfQuarterlyInstallment", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails", "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails" ], "xbrltype": "integerItemType" }, "hook_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The weighted average grant date fair value price of shares issued at grant date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Weighted Average Grant Date Fair Value", "terseLabel": "Grant date fair value per share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationCommonStockAwardsDetails" ], "xbrltype": "perShareItemType" }, "hook_ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of common stock entitled for each option upon the exercise of the option.", "label": "Share-based Payment Arrangement, Option, Number of Common Stock Entitled for Each Option", "terseLabel": "Number of common stock entitled for each option upon the exercise of the option" } } }, "localname": "ShareBasedPaymentArrangementOptionNumberOfCommonStockEntitledForEachOption", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails" ], "xbrltype": "sharesItemType" }, "hook_SharesConversionRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of stock.", "label": "Shares Conversion Ratio" } } }, "localname": "SharesConversionRatio", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails" ], "xbrltype": "pureItemType" }, "hook_SharesGrantedValueShareBasedPaymentArrangementVested": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of vested shares granted under share-based payment arrangement.", "label": "Shares Granted, Value, Share-based Payment Arrangement, Vested", "terseLabel": "Vesting of equity grants" } } }, "localname": "SharesGrantedValueShareBasedPaymentArrangementVested", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "hook_SharesIssuedSharesShareBasedPaymentArrangementVested": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares (or other type of equity) vested during the period.", "label": "Shares Issued, Shares, Share-based Payment Arrangement, Vested", "terseLabel": "Vesting of equity grants (in shares)" } } }, "localname": "SharesIssuedSharesShareBasedPaymentArrangementVested", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "hook_StockIncentivePlanArrangementCumulativeAnnualIncreaseInIssuanceOfPercentageOfOutstandingShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of the then outstanding number of shares which will be the cumulative annual increase in issuance under the stock incentive plan.", "label": "Stock Incentive Plan Arrangement, Cumulative Annual Increase In Issuance Of Percentage Of Outstanding Shares", "terseLabel": "Number of shares outstanding were cumulatively increased" } } }, "localname": "StockIncentivePlanArrangementCumulativeAnnualIncreaseInIssuanceOfPercentageOfOutstandingShares", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails" ], "xbrltype": "percentItemType" }, "hook_StockIssuedDuringPeriodSharesRestrictedStockAwardVested": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares related to Restricted Stock Award vested during the period.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Vested", "terseLabel": "Vesting of restricted stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardVested", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "hook_StockIssuedDuringPeriodValueRestrictedStockAwardVested": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards vested during the period.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Vested", "terseLabel": "Vesting of restricted stock" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardVested", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "hook_StockOptionAndGrant2018PlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to 2018 stock option and grant plan.", "label": "2018 Stock Option and Grant Plan" } } }, "localname": "StockOptionAndGrant2018PlanMember", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails" ], "xbrltype": "domainItemType" }, "hook_StockOptionAndIncentive2019PlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to 2019 stock option and incentive plan.", "label": "2019 Stock Option and Incentive Plan" } } }, "localname": "StockOptionAndIncentive2019PlanMember", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails" ], "xbrltype": "domainItemType" }, "hook_StockPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to stock purchase agreement.", "label": "Stock Purchase Agreement" } } }, "localname": "StockPurchaseAgreementMember", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnauditedParenthetical" ], "xbrltype": "domainItemType" }, "hook_ThresholdPercentageForConversion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum percent of common stock that can be owned after conversion of preferred stock.", "label": "Threshold Percentage For Conversion", "terseLabel": "Threshold percentage for conversion" } } }, "localname": "ThresholdPercentageForConversion", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails" ], "xbrltype": "percentItemType" }, "hook_TotalMilestoneAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total milestone amount.", "label": "Total Milestone Amount", "terseLabel": "Total milestone amount" } } }, "localname": "TotalMilestoneAmount", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails", "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "hook_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedBeforeConversion": { "auth_ref": [], "calculation": { "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS), before taking into consideration Series A convertible preferred shares outstanding converted into common stock.", "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted, Before Conversion", "terseLabel": "Weighted-average common shares outstanding, basic and diluted" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasicAndDilutedBeforeConversion", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "hook_WeightedAverageSeriesConvertiblePreferredSharesOutstandingConvertedIntoCommonStock": { "auth_ref": [], "calculation": { "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Weighted-average Series A convertible preferred shares outstanding, basic and diluted, presented as if converted into common stock.", "label": "Weighted-average Series A convertible Preferred Shares Outstanding, Converted into Common Stock", "terseLabel": "Weighted-average Series A convertible preferred shares outstanding, basic and diluted, presented as if converted into common stock" } } }, "localname": "WeightedAverageSeriesConvertiblePreferredSharesOutstandingConvertedIntoCommonStock", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "hook_WeightedAverageSeriesOneConvertiblePreferredSharesOutstandingConvertedIntoCommonStock": { "auth_ref": [], "calculation": { "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails": { "order": 3.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Weighted-average Series A-1 convertible preferred shares outstanding, basic and diluted, presented as if converted into common stock.", "label": "Weighted-average Series A One convertible Preferred Shares Outstanding, Converted into Common Stock", "terseLabel": "Weighted-average Series A-1 convertible preferred shares outstanding, basic and diluted, presented as if converted into common stock" } } }, "localname": "WeightedAverageSeriesOneConvertiblePreferredSharesOutstandingConvertedIntoCommonStock", "nsuri": "http://www.hookipapharma.com/20220930", "presentation": [ "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": { "auth_ref": [ "r417" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.", "label": "Contractual Obligation, Fiscal Year Maturity [Table Text Block]", "terseLabel": "Schedule of aggregate minimum future principal payments due in connection with the FFG Loans" } } }, "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureLoansPayableTables" ], "xbrltype": "textBlockItemType" }, "srt_MaximumMember": { "auth_ref": [ "r166", "r167", "r168", "r169", "r184", "r193", "r236", "r237", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r395", "r396", "r408", "r409" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails", "http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingenciesOperatingAndFinanceLeasesDetails", "http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingenciesOthersDetails", "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r166", "r167", "r168", "r169", "r184", "r193", "r236", "r237", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r395", "r396", "r408", "r409" ], "lang": { "en-us": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.", "label": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.", "label": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r161", "r166", "r167", "r168", "r169", "r184", "r193", "r227", "r236", "r237", "r269", "r270", "r271", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r395", "r396", "r408", "r409" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails", "http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingenciesOperatingAndFinanceLeasesDetails", "http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingenciesOthersDetails", "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r161", "r166", "r167", "r168", "r169", "r184", "r193", "r227", "r236", "r237", "r269", "r270", "r271", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r395", "r396", "r408", "r409" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails", "http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingenciesOperatingAndFinanceLeasesDetails", "http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingenciesOthersDetails", "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r148", "r349" ], "lang": { "en-us": { "role": { "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails", "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Title of individual, or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails", "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of significant accounting policies" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.", "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "terseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r26", "r352" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r149", "r150" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, Net, Current", "terseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "auth_ref": [ "r28" ], "calculation": { "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 1.0, "parentTag": "hook_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Employee Benefits, Current", "terseLabel": "Salaries and bonuses" } } }, "localname": "AccruedEmployeeBenefitsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r10", "r157" ], "calculation": { "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r21", "r37", "r38", "r39", "r385", "r401", "r402" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r36", "r39", "r45", "r46", "r47", "r86", "r87", "r88", "r307", "r348", "r397", "r398" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "Accumulated Other Comprehensive Loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r19", "r352" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r86", "r87", "r88", "r278", "r279", "r280", "r313" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r239", "r281", "r282" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "auth_ref": [ "r206", "r210" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.", "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "verboseLabel": "Issuance costs" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnauditedParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r108" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Anti-dilutive shares" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r108" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Anti-dilutive securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r108" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Arrangements and Non-arrangement Transactions [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails", "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails", "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r12", "r81", "r134", "r137", "r143", "r152", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r303", "r308", "r324", "r350", "r352", "r370", "r383" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r3", "r25", "r81", "r152", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r303", "r308", "r324", "r350", "r352" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r316" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "terseLabel": "Total" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsNoncurrent": { "auth_ref": [ "r81", "r152", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r303", "r308", "r324", "r350" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.", "label": "Assets, Noncurrent", "totalLabel": "Total non-current assets" } } }, "localname": "AssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Noncurrent [Abstract]", "terseLabel": "Non-current assets:" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r242", "r243", "r244", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r255", "r256", "r257", "r258", "r259", "r260", "r262", "r263", "r265", "r266", "r268", "r269", "r270", "r271", "r272" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationCommonStockAwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r8", "r70" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r71" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r64", "r70", "r76" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r64", "r325" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental disclosure of non-cash financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r15", "r17", "r18", "r79", "r81", "r101", "r102", "r103", "r105", "r107", "r115", "r116", "r117", "r152", "r172", "r176", "r177", "r178", "r181", "r182", "r191", "r192", "r195", "r199", "r206", "r324", "r416" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails", "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnauditedParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r298", "r299", "r301" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Collaboration and Licensing Agreements" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementMember": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.", "label": "Gilead Collaboration and License Agreement" } } }, "localname": "CollaborativeArrangementMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails", "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]", "terseLabel": "Collaboration and Licensing Agreements" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r33", "r373", "r389" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies.", "terseLabel": "Commitments and contingencies (Note 12)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r163", "r164", "r165", "r170", "r404" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation.", "label": "Class A common stock" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails", "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r86", "r87", "r313" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued", "verboseLabel": "Common stock, issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r18", "r206" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding", "verboseLabel": "Common stock, outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r18", "r352" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r41", "r43", "r44", "r51", "r376", "r391" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r121", "r381" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentrations of credit risk and of significant suppliers" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r212", "r213", "r224" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred revenues" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r212", "r213", "r224" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Contract with Customer, Liability, Noncurrent", "terseLabel": "Deferred revenues, non-current" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.", "label": "Contractual Obligation", "terseLabel": "Non-cancellable obligations" } } }, "localname": "ContractualObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingenciesOthersDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligationDueInNextTwelveMonths": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Contractual Obligation, Due in Next Fiscal Year", "terseLabel": "2023 deliverables" } } }, "localname": "ContractualObligationDueInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingenciesOthersDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligationDueInSecondYear": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Contractual Obligation, Due in Second Year", "terseLabel": "2024 deliverables" } } }, "localname": "ContractualObligationDueInSecondYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingenciesOthersDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation to be paid in remainder of current fiscal year.", "label": "Contractual Obligation, Future Minimum Payments Due, Remainder of Fiscal Year", "terseLabel": "2022 deliverables (remaining three months)" } } }, "localname": "ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingenciesOthersDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockAmountIssued1": { "auth_ref": [ "r73", "r74", "r75" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Amount Issued", "terseLabel": "Conversion of Class A common stock to common stock" } } }, "localname": "ConversionOfStockAmountIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockSharesConverted1": { "auth_ref": [ "r73", "r74", "r75" ], "lang": { "en-us": { "role": { "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Shares Converted", "terseLabel": "Number of shares elected to convert" } } }, "localname": "ConversionOfStockSharesConverted1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ConversionOfStockSharesIssued1": { "auth_ref": [ "r73", "r74", "r75" ], "lang": { "en-us": { "role": { "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Shares Issued", "terseLabel": "Shares issued upon conversion of redeemable convertible preferred stock (in shares)", "verboseLabel": "Conversion of Class A common stock to common stock (in shares)" } } }, "localname": "ConversionOfStockSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails", "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "auth_ref": [ "r16", "r17", "r202", "r207", "r209" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.", "label": "Convertible Preferred Stock, Shares Issued upon Conversion", "terseLabel": "Number of common stock issued upon conversion of each share of Preferred Stock" } } }, "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r54" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Operating Costs and Expenses", "negatedTotalLabel": "Total operating expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r30", "r183" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate (as a percent)" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent": { "auth_ref": [ "r334", "r336" ], "calculation": { "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermLoansPayable", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of debt discount to be amortized after one year or the normal operating cycle, if longer.", "label": "Debt Instrument, Unamortized Discount, Noncurrent", "negatedLabel": "Unamortized debt discount" } } }, "localname": "DebtInstrumentUnamortizedDiscountNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r68", "r132" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization expense" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r241", "r242", "r273", "r274", "r275", "r283" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]", "terseLabel": "Stock-based compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock-based compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net loss per share" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r52", "r91", "r92", "r93", "r94", "r95", "r99", "r101", "r105", "r106", "r107", "r111", "r112", "r314", "r315", "r377", "r392" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "verboseLabel": "Net loss per share - basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r52", "r91", "r92", "r93", "r94", "r95", "r101", "r105", "r106", "r107", "r111", "r112", "r314", "r315", "r377", "r392" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "verboseLabel": "Net loss per share - diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r108", "r109", "r110", "r113" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net loss per share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureNetLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r325" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Laboratory equipment" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails", "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r45", "r46", "r47", "r86", "r87", "r88", "r90", "r96", "r98", "r114", "r153", "r206", "r210", "r278", "r279", "r280", "r289", "r290", "r313", "r326", "r327", "r328", "r329", "r330", "r331", "r348", "r397", "r398", "r399" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value of Financial Assets" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r316", "r317", "r322" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r316", "r317" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of financial assets measured at fair value on a recurring basis" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r186", "r189", "r190", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r317", "r356", "r357", "r358" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r316", "r317", "r318", "r319", "r323" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Assets" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r321" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value of Financial Assets" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r186", "r228", "r229", "r234", "r235", "r317", "r356" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Fair Value, Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair value measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": { "auth_ref": [ "r320" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3", "terseLabel": "Transfers from into Level 3" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": { "auth_ref": [ "r320" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3", "terseLabel": "Transfers from out of Level 3" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r186", "r189", "r190", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r356", "r357", "r358" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r321", "r323" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r338" ], "calculation": { "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 2.0, "parentTag": "hook_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "netLabel": "Outstanding finance lease obligations", "verboseLabel": "Finance lease liabilities" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails", "http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingenciesOperatingAndFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes current finance lease liability.", "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]" } } }, "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingenciesOperatingAndFinanceLeasesDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r340", "r343" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "negatedLabel": "Payments related to finance leases" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r337" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset", "terseLabel": "Finance lease right of use assets", "verboseLabel": "Finance lease right-of-use assets" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingenciesOperatingAndFinanceLeasesDetails", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails", "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r55" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense.", "negatedLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r53" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r49", "r134", "r136", "r139", "r142", "r144", "r369", "r374", "r379", "r393" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Net loss before tax" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED)" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r159", "r162" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r162" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income taxes" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r82", "r286", "r287", "r288", "r291", "r293", "r295", "r296", "r297" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r83", "r97", "r98", "r133", "r285", "r292", "r294", "r394" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Income tax expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r72" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "negatedLabel": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r67" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r67" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r67", "r366" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Deferred revenues" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r67", "r343" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Increase (Decrease) in Operating Lease Liabilities", "terseLabel": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r67" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedLabel": "Other non-current assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.", "label": "Increase (Decrease) in Other Noncurrent Liabilities", "terseLabel": "Other non-current liabilities" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r48", "r131", "r333", "r335", "r378" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r62", "r65", "r72" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "negatedLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r56", "r130" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LandMember": { "auth_ref": [ "r225" ], "lang": { "en-us": { "role": { "documentation": "Part of earth's surface not covered by water.", "label": "Land" } } }, "localname": "LandMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r156" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Leases" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingenciesOperatingAndFinanceLeasesDetails", "http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingenciesOthersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r342" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingenciesOperatingAndFinanceLeasesDetails", "http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingenciesOthersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r341" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r27", "r81", "r138", "r152", "r172", "r173", "r174", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r304", "r308", "r309", "r324", "r350", "r351" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r24", "r81", "r152", "r324", "r352", "r372", "r387" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders' Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r4", "r29", "r81", "r152", "r172", "r173", "r174", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r304", "r308", "r309", "r324", "r350", "r351", "r352" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r5", "r6", "r7", "r13", "r14", "r81", "r152", "r172", "r173", "r174", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r304", "r308", "r309", "r324", "r350", "r351" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "Total non-current liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Non-current liabilities" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LoansPayable": { "auth_ref": [ "r13", "r371", "r382" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).", "label": "Loans Payable.", "terseLabel": "Loans payable, non-current" } } }, "localname": "LoansPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LoansPayableCurrent": { "auth_ref": [ "r28" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.", "label": "Loans Payable, Current", "terseLabel": "Loans payable, current" } } }, "localname": "LoansPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r13", "r185", "r188", "r189", "r190", "r371", "r384" ], "calculation": { "http://www.hookipapharma.com/role/DisclosureLoansPayableScheduleOfAggregateMinimumFuturePrincipalPaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long-term Debt", "totalLabel": "Total" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureLoansPayableScheduleOfAggregateMinimumFuturePrincipalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtByMaturityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-term Debt, Fiscal Year Maturity [Abstract]" } } }, "localname": "LongTermDebtByMaturityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureLoansPayableScheduleOfAggregateMinimumFuturePrincipalPaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r84", "r171", "r187" ], "calculation": { "http://www.hookipapharma.com/role/DisclosureLoansPayableScheduleOfAggregateMinimumFuturePrincipalPaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureLoansPayableScheduleOfAggregateMinimumFuturePrincipalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r84", "r171", "r187" ], "calculation": { "http://www.hookipapharma.com/role/DisclosureLoansPayableScheduleOfAggregateMinimumFuturePrincipalPaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Two", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureLoansPayableScheduleOfAggregateMinimumFuturePrincipalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermLoansPayable": { "auth_ref": [ "r31" ], "calculation": { "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Loans Payable, Noncurrent", "totalLabel": "Total loans payable, net" } } }, "localname": "LongTermLoansPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermLoansPayableAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loans payable" } } }, "localname": "LongTermLoansPayableAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.", "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners", "terseLabel": "Ownership percentage" } } }, "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails" ], "xbrltype": "percentItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r118", "r127" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "Nature of the business and organization" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureNatureOfBusinessAndOrganization" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r64" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r64" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r64", "r66", "r69" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by (used in) operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r40", "r42", "r47", "r50", "r69", "r81", "r89", "r91", "r92", "r93", "r94", "r97", "r98", "r104", "r134", "r136", "r139", "r142", "r144", "r152", "r172", "r173", "r174", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r315", "r324", "r375", "r390" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net losses" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails", "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesGoingConcernDetails", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Parent [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "NetIncomeLossAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent accounting pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r57" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r134", "r136", "r139", "r142", "r144" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r338" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Outstanding operating lease obligations" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingenciesOperatingAndFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r338" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current operating lease liability", "verboseLabel": "Operating lease liabilities, current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingenciesOperatingAndFinanceLeasesDetails", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r338" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Non-current operating lease liability", "verboseLabel": "Operating lease liabilities, non-current" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingenciesOperatingAndFinanceLeasesDetails", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r337" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right of use assets", "verboseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingenciesOperatingAndFinanceLeasesDetails", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r346", "r347" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "verboseLabel": "Weighted average discount rate on operating lease liabilities (as a percent)" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingenciesOperatingAndFinanceLeasesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r345", "r347" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "verboseLabel": "Weighted average lease term remaining on operating lease liabilities (in years)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingenciesOperatingAndFinanceLeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nature of the business and organization" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r11" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other non-current assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r35" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustment, net of tax", "verboseLabel": "Foreign currency translation gain (loss), net of tax" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive loss:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r32" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other non-current liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r69" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other non-cash items" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r58" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income and (expenses), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense):" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r59" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r242", "r243", "r244", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r255", "r256", "r257", "r258", "r259", "r260", "r262", "r263", "r265", "r266", "r268", "r269", "r270", "r271", "r272" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails", "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r242", "r243", "r244", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r255", "r256", "r257", "r258", "r259", "r260", "r262", "r263", "r265", "r266", "r268", "r269", "r270", "r271", "r272" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails", "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockLiquidationPreference": { "auth_ref": [ "r17", "r79", "r195", "r207", "r208" ], "lang": { "en-us": { "role": { "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.", "label": "Preferred Stock, Liquidation Preference Per Share", "terseLabel": "Liquidation preference per share" } } }, "localname": "PreferredStockLiquidationPreference", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r17", "r191" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "verboseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r17", "r191" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "verboseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "verboseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r17", "r352" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred stock, $0.0001 par value; 10,000,000 shares authorized at September 30, 2022 and December 31, 2021, respectively; Series A convertible preferred stock, 2,978 shares designated, 1,697 shares outstanding at September 30, 2022 and December 31, 2021, respectively; Series A-1 convertible preferred stock, 15,800 shares and no shares designated, 15,800 shares and no shares outstanding at September 30, 2022 and December 31, 2021, respectively" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r60" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": { "auth_ref": [ "r60" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.", "label": "Proceeds from Issuance of Convertible Preferred Stock", "terseLabel": "Proceeds from issuance of convertible preferred stock, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r60" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Proceeds from Issuance or Sale of Equity", "verboseLabel": "Net proceeds from public offering" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r60", "r277" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Cash received from option exercise under share-based payment arrangements" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r1", "r40", "r42", "r47", "r63", "r81", "r89", "r97", "r98", "r134", "r136", "r139", "r142", "r144", "r152", "r172", "r173", "r174", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r302", "r305", "r306", "r310", "r311", "r315", "r324", "r379" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r158" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails", "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r160", "r405", "r406", "r407" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r9", "r156" ], "calculation": { "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails", "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r158", "r352", "r380", "r388" ], "calculation": { "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, plant and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, plant and equipment, net." } } }, "localname": "PropertyPlantAndEquipmentNetAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r158", "r405", "r406" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r158" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r156" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails", "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Estimated useful life (in years)" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r61" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments of Debt", "negatedLabel": "Repayments of borrowings", "terseLabel": "Principal payment" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureLoansPayableDetails", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r284", "r367", "r410" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense.", "negatedLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": { "auth_ref": [ "r154", "r155", "r410" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.", "label": "Research, Development, and Computer Software, Policy [Policy Text Block]", "terseLabel": "Capitalized Software Development Cost" } } }, "localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureFairValueOfFinancialAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r8", "r76" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Current", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r11", "r76", "r403" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted cash", "verboseLabel": "Cash balance maintained to secure a letter of credit associated with a real estate lease" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommitmentsAndContingenciesOperatingAndFinanceLeasesDetails", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted stock units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r20", "r210", "r352", "r386", "r400", "r402" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesGoingConcernDetails", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r86", "r87", "r88", "r90", "r96", "r98", "r153", "r278", "r279", "r280", "r289", "r290", "r313", "r397", "r399" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r128", "r129", "r135", "r140", "r141", "r145", "r146", "r147", "r222", "r223", "r368" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenue from collaboration and licensing" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r78", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r226" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue recognition from contracts with customers" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList": { "auth_ref": [ "r225" ], "lang": { "en-us": { "role": { "documentation": "Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.", "label": "Revenue from Contract with Customer, Product and Service [Extensible List]" } } }, "localname": "RevenueFromContractWithCustomerProductAndServiceExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r344", "r347" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "verboseLabel": "Lease assets obtained in exchange for new operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnauditedParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r108" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r108" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of potentially dilutive securities that were not included in the diluted per share calculations" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r107" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of basic and diluted net loss per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r158" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property and equipment, net" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosurePropertyPlantAndEquipmentNetDetails", "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "auth_ref": [ "r254", "r261", "r264" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.", "label": "Share-based Compensation, Activity [Table Text Block]", "terseLabel": "Schedule of stock-based compensation expense" } } }, "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r238", "r240", "r242", "r243", "r244", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r255", "r256", "r257", "r258", "r259", "r260", "r262", "r263", "r265", "r266", "r268", "r269", "r270", "r271", "r272" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails", "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails", "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationCommonStockAwardsDetails", "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r245", "r261", "r264" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]", "terseLabel": "Schedule of summary of stock option activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of assumptions used in the Black-Scholes option-pricing model for estimating the fair value of stock options" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r67" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Compensation", "terseLabel": "Stock-based compensation expense", "verboseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r242" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails", "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails", "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "verboseLabel": "Share-based awards granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationCommonStockAwardsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]", "terseLabel": "Assumptions used in the Black-Scholes option-pricing model" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionValuationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r269" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionValuationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionValuationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails", "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails", "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationCommonStockAwardsDetails", "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r244" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Number stock option authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Weighted Average Remaining Contractual Term" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r248" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Option exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r248" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Option exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r252" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r250" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "verboseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r276" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "periodEndLabel": "Aggregate Intrinsic Value, ending balance", "periodStartLabel": "Aggregate Intrinsic Value, beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r246", "r247" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Options outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails", "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r246", "r247" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Averaged Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r242", "r243", "r244", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r255", "r256", "r257", "r258", "r259", "r260", "r262", "r263", "r265", "r266", "r268", "r269", "r270", "r271", "r272" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationCommonStockAwardsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r251" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r252" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r250" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted", "verboseLabel": "Exercise price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Vesting upon first anniversary" } } }, "localname": "ShareBasedCompensationAwardTrancheOneMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails", "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails", "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Vesting in equal quarterly installments" } } }, "localname": "ShareBasedCompensationAwardTrancheTwoMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails", "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails", "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "verboseLabel": "Share price (in USD per share)" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails", "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationCommonStockAwardsDetails", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r242" ], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Percentage of options vesting" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails", "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails", "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionValuationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r276" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, option exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r276" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term, option exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-vested options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares", "terseLabel": "Option unvested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price", "terseLabel": "Option unvested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r265" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance at the end of the period (in shares)", "periodStartLabel": "Balance at the beginning of the period (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r77", "r85" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of significant accounting policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r15", "r17", "r18", "r79", "r81", "r101", "r102", "r103", "r105", "r107", "r115", "r116", "r117", "r152", "r172", "r176", "r177", "r178", "r181", "r182", "r191", "r192", "r195", "r199", "r206", "r324", "r416" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails", "http://www.hookipapharma.com/role/DocumentDocumentAndEntityInformation", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnauditedParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r34", "r45", "r46", "r47", "r86", "r87", "r88", "r90", "r96", "r98", "r114", "r153", "r206", "r210", "r278", "r279", "r280", "r289", "r290", "r313", "r326", "r327", "r328", "r329", "r330", "r331", "r348", "r397", "r398", "r399" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnauditedParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED BALANCE SHEETS" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (UNAUDITED)" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r86", "r87", "r88", "r114", "r368" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnauditedParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockCompensationPlanMember": { "auth_ref": [ "r108" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.", "label": "Common Stock Awards" } } }, "localname": "StockCompensationPlanMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationCommonStockAwardsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r17", "r18", "r206", "r210" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of stock (in shares)", "verboseLabel": "Issuance of common stock" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r17", "r18", "r206", "r210", "r251" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised", "verboseLabel": "Issuance of common stock upon exercise of stock options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r17", "r18", "r206", "r210" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of stock" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r34", "r206", "r210" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Issuance of common stock upon exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r18", "r22", "r23", "r81", "r151", "r152", "r324", "r352" ], "calculation": { "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance at the end of the period", "periodStartLabel": "Balance at the beginning of the period", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock, Class A common stock and convertible preferred stock" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r80", "r192", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r203", "r204", "r205", "r210", "r211", "r312" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Common stock, Class A common stock and convertible preferred stock" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStock" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r332", "r354" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r332", "r354" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r332", "r354" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r332", "r354" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r353", "r355" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureSubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnaudited", "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityUnauditedParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Type of Arrangement and Non-arrangement Transactions [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureCollaborationAndLicensingAgreementsDetails", "http://www.hookipapharma.com/role/DisclosureCommonStockClassCommonStockAndConvertiblePreferredStockDetails", "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r119", "r120", "r122", "r123", "r124", "r125", "r126" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r242", "r243", "r244", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r255", "r256", "r257", "r258", "r259", "r260", "r262", "r263", "r265", "r266", "r268", "r269", "r270", "r271", "r272" ], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails", "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails", "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r242", "r243", "r244", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r255", "r256", "r257", "r258", "r259", "r260", "r262", "r263", "r265", "r266", "r268", "r269", "r270", "r271", "r272" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Domain]" } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2018StockOptionAndGrantPlanDetails", "http://www.hookipapharma.com/role/DisclosureStockBasedCompensation2019StockOptionAndIncentivePlanDetails", "http://www.hookipapharma.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r100", "r107" ], "calculation": { "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Total number of shares used to calculate net loss per share, diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Denominator:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r99", "r107" ], "calculation": { "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "totalLabel": "Total number of shares used to calculate net loss per share, basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.hookipapharma.com/role/DisclosureNetLossPerShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r113": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r127": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "40", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=16397303&loc=d3e19347-109286" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r165": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r211": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r226": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907" }, "r283": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r297": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r301": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "https://asc.fasb.org/topic&trid=5833765" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r355": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16)(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r411": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r412": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r413": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r414": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r415": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r416": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r417": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "303", "Subparagraph": "(5)" }, "r418": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r419": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r85": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" } }, "version": "2.1" }